Atea Pharmaceuticals. has filed a patent for a hemi-sulfate salt structure to treat hepatitis C infections in hosts. The patent includes pharmaceutical compositions and solid dosage forms. GlobalData’s report on Atea Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Atea Pharmaceuticals Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Atea Pharmaceuticals, Recombinant AAV gene therapy was a key innovation area identified from patents. Atea Pharmaceuticals's grant share as of January 2024 was 32%. Grant share is based on the ratio of number of grants to total number of patents.

Treatment for hepatitis c using hemi-sulfate salt

Source: United States Patent and Trademark Office (USPTO). Credit: Atea Pharmaceuticals Inc

The filed patent (Publication Number: US20240018179A1) describes a process for preparing Compound 2, with specific steps outlined for the synthesis. The process involves dissolving Compound 1 in an organic solvent, with the ratio of H2SO4 to Compound 1 specified. The organic solvents used in the process include acetone, ethyl acetate, methanol, acetonitrile, and ether, with variations such as 3-methyl-2-pentanone, ethyl isopropyl ketone, methyl propionate, and ethyl butyrate also mentioned. The patent further details the drying of Compound 2 in a vacuum and the washing of the Compound 2 precipitate with various organic solvent mixtures.

Additionally, the patent specifies the cooling of the H2SO4/methanol mixture before addition to the Compound 1 solution and the drying of Compound 2 in a vacuum at a specific temperature range. The process variations include different combinations of organic solvents, H2SO4/solvent mixtures, and washing solvent mixtures, providing flexibility in the synthesis process. The detailed steps outlined in the patent aim to ensure the efficient and reproducible preparation of Compound 2, highlighting the importance of specific conditions and solvents in the synthesis process.

To know more about GlobalData’s detailed insights on Atea Pharmaceuticals, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies